1-3 of 3
Peter Adamson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I Study of 90 Y-Ibritumomab-Tiuxetan ( 90 Y-It) in Children with Recurrent/Refractory CD20 Positive Lymphoma: A Cog Phase I Consortium Study.

Mitchell S. Cairo, MD, Erin Cooney, CPNP, Mark Krailo, PhD, Richard Belanger, MS, CHP, Sherrie L. Perkins, MD, PhD, Rashid Fawwaz, MD, Anne Angiolillo, MD, Peter Adamson, MD
Journal: Blood
Blood (2005) 106 (11): 2448.
https://doi.org/10.1182/blood.V106.11.2448.2448
Published: 2005
Journal Articles

A Phase I Study of Temozolomide (Temodar®) in Pediatric Patients with Relapsed or Refractory Leukemia—A Children’s Oncology Group Study.

Terzah M. Horton, MD, PhD, Eileen Dolan, PhD, Madhuri Hegde, PhD, Stacey L. Berg, MD, Peter Adamson, MD, Susan M. Blaney, MD
Journal: Blood
Blood (2005) 106 (11): 4455.
https://doi.org/10.1182/blood.V106.11.4455.4455
Published: 2005
Journal Articles

T-cell interaction with ICAM-1/ICAM-2 double-deficient brain endothelium in vitro: the cytoplasmic tail of endothelial ICAM-1 is necessary for transendothelial migration of T cells

Ruth Lyck, Yvonne Reiss, Nicole Gerwin, John Greenwood, Peter Adamson, Britta Engelhardt
Journal: Blood
Blood (2003) 102 (10): 3675–3683.
https://doi.org/10.1182/blood-2003-02-0358
Published: 2003
Includes: Supplemental data